[Featured Stock] Jinwon Life Sciences Surges Early Session 9.93% Up

[Asia Economy Reporter Park So-yeon] Jinwon Life Sciences is showing strong performance in the early trading session following securities analysts' reports that it is capable of producing the world's largest scale of mRNA materials.

As of 9:55 AM on the 26th, Jinwon Life Sciences is trading on the KOSPI market at 24,350 KRW, up 2,200 KRW (9.93%) from the previous day.

Oh Byung-yong, a researcher at Hanyang Securities, stated, "Jinwon Life Sciences owns a cGMP-grade Plasmid DNA production plant in the United States and is currently expanding a large-scale new plant. The new plant will cover 6,800 pyeong, and upon completion in the fourth quarter of this year, it will become the world's largest Plasmid DNA factory."

He added, "The current world's largest Plasmid DNA factory is Aldevron's new plant in the U.S. Aldevron was recognized with a corporate value of 4 trillion KRW in 2019 related to this and attracted investment."

He emphasized, "In fact, 2019 was a time when mRNA did not even exist, yet it was valued that highly. Now that BioNTech and Moderna's mRNA have become global hits and the demand for the raw material Plasmid DNA has surged, it is estimated to receive an even greater value."

Jinwon Life Sciences' plant is larger than Aldevron's, and its completion date is only about six months later. Researcher Oh pointed out that a deep consideration is needed regarding the value of this new plant.

This content was produced with the assistance of AI translation services.